WO2002078703A1 - Use of cyclopamine in the treatment of basal cell carcinoma and other tumors - Google Patents

Use of cyclopamine in the treatment of basal cell carcinoma and other tumors Download PDF

Info

Publication number
WO2002078703A1
WO2002078703A1 PCT/TR2001/000027 TR0100027W WO02078703A1 WO 2002078703 A1 WO2002078703 A1 WO 2002078703A1 TR 0100027 W TR0100027 W TR 0100027W WO 02078703 A1 WO02078703 A1 WO 02078703A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclopamine
cells
bcc
treatment
basal cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2001/000027
Other languages
English (en)
French (fr)
Other versions
WO2002078703A8 (en
Inventor
Sinan Tas
Oktay Avci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002078703(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PCT/TR2001/000027 priority Critical patent/WO2002078703A1/en
Priority to AT01952097T priority patent/ATE305300T1/de
Priority to EP10163813.8A priority patent/EP2216022B1/en
Priority to AU2001272892A priority patent/AU2001272892B8/en
Priority to EP20140196071 priority patent/EP2862570A1/en
Priority to EP01952097A priority patent/EP1401438B1/en
Priority to DK01952097T priority patent/DK1401438T3/da
Priority to EP05008758A priority patent/EP1561464A3/en
Priority to ES01952097T priority patent/ES2250434T3/es
Application filed by Individual filed Critical Individual
Priority to JP2002576969A priority patent/JP2004536045A/ja
Priority to DE60113733T priority patent/DE60113733T2/de
Priority to BR0117063-5A priority patent/BR0117063A/pt
Priority to ES10163813.8T priority patent/ES2534400T3/es
Priority to CA2452151A priority patent/CA2452151C/en
Priority to CN018234429A priority patent/CN1525859B/zh
Priority to AT02736467T priority patent/ATE299022T1/de
Priority to PCT/TR2002/000017 priority patent/WO2002078704A1/en
Priority to CA002452152A priority patent/CA2452152A1/en
Priority to ES02736467T priority patent/ES2246011T3/es
Priority to DK02736467T priority patent/DK1411938T3/da
Priority to DE60204966T priority patent/DE60204966T2/de
Priority to RU2004103074/15A priority patent/RU2312661C2/ru
Priority to CNB02813429XA priority patent/CN1230169C/zh
Priority to EP02736467A priority patent/EP1411938B1/en
Priority to PT02736467T priority patent/PT1411938E/pt
Publication of WO2002078703A1 publication Critical patent/WO2002078703A1/en
Priority to KR1020097022024A priority patent/KR20090125833A/ko
Publication of WO2002078703A8 publication Critical patent/WO2002078703A8/en
Priority to US10/682,662 priority patent/US7605167B2/en
Priority to US10/682,584 priority patent/US7893078B2/en
Anticipated expiration legal-status Critical
Priority to US11/874,653 priority patent/US7629352B2/en
Priority to US11/874,631 priority patent/US8025893B2/en
Priority to US12/460,620 priority patent/US9757361B2/en
Priority to JP2010028010A priority patent/JP5424923B2/ja
Priority to US12/930,677 priority patent/US20110104254A1/en
Priority to JP2013193304A priority patent/JP2014028834A/ja
Priority to US15/530,513 priority patent/US20170326118A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention concerns the use of cyclopamine in vivo on basal cell carcinomas (BCC's) to achieve therapeutic effect by causing differentiation of the tumor cells and, at the same time, apoptotic death and removal of these tumor cells while preserving the normal tissue cells, including the u ⁇ differentiated cells of the normal epidermal basal layer and hair follicles.
  • BCC's basal cell carcinomas
  • Basal cell carcinoma is a common epithelial tumor. Its incidence increases with increasing age. Current treatments for BCC's include the surgical excision of the tumor together with a margin of normal tissue and, when surgery is not feasible or desirable, destruction of the tumor cells by ionizing radiation or other means. Although scarring and disfigurement are potential side effects, surgical excisions that do not leave neoplastic cells behind can provide cure. Radiation therapy acts by causing irreparably high quantity of DNA-damage which, in turn, triggers apoptotic death of the tumor cells. This mode of action of radiation- therapy, i.e. apoptosis secondary to DNA-damage, is similar to those of many chemotherapeutic agents that are currently used in the treatment of cancers.
  • BCC's frequently show inactivating mutations of the gene patched which encodes a transmembrane protein acting as a receptor for the hedgehog proteins identified first by their effect on the patterning of tissues during development.
  • the patched protein acts to inhibit intracellular signal transduction by another transmembrane protein, smoothened. Binding of hedgehog to the patched causes relieving of this inhibition. Intracellular signal transduction by the relieved smoofftened then initiates a series of cellular events resulting ultimately in alterations of the expressions of the hedgehog target genes and of cellular behaviour.
  • Cyclopamine a steroid alkaloid, has the chemical formula shown below.
  • cyclopamine can be dissolved in ethanol or another suitable solvent and mixed with a suitable base cream, ointment or gel. Cyclopamine may also be entrapped in hydrogels or in other pharmaceutical forms enabling controlled release and may be adsorbed onto dermal patches.
  • the effects shown in figures Fig 1Ato Fig 1D, Fig 2Ato Fig 2F, Fig 3Ato Fig 3G and Fig 4Ato Fig 4D have been obtained by a cream preparation obtained by mixing a solution of cyclopamine in ethanol with a base cream so as to get a final concentration of 18 mM cyclopamine in cream.
  • the base cream used is made predominantly of heavy paraffin oil( 10% ww), vaseline (10% w/w), stearyl alcohol (8% w/w), polyoxylsteareth-40 (3% w/w) and water (68% w/w) but another suitably formulated base cream is also possible.
  • Optimal concentration of cyclopamine in a pharmaceutical form as well as the optimal dosing and application schedules can obviously be affected by such factors as the particular pharmaceutical form, the localisation and characteristics of the skin containing the tumor (e.g. thickness of the epidermis) and the tumor size; however these can be determined by following well known published optimisation methods.
  • Fig 1 A BCC on the nasolabial fold, ⁇ 4x5 mm on surface
  • Fig 1C BCC on the forehead, ⁇ 4x4 mm on surface
  • Night-time applications, avoided in this schedule because of possible loss of cream from the patient skin to linens during sleep, can be performed by suitable dermal patches.
  • preservation of the undifferentiated cells in the normal epidermis and in hair follicles following exposure to cyclopamine provide information about the tolerable doses in other possible modes of administration as well; e.g. direct intratumoral injection of an aqueous solution or systemic administration of the same or of cyclopamine entrapped in liposomes.
  • Fig 1A, Fig 1B, Fig 1C and Fig 1D show rapid clinical regressions of the BCC's following exposure to cyclopamine. Besides the visual disappearence of several tumor areas within less than a week of cyclopamine exposure, there is a loss in the typically translucent appearance of the BCC's as seen by the comparison of Fig 1B to Fig 1A and of Fig 1Dto Fig 1C.
  • Fig 2A to Fig 2F show microscopic appearances of the tumor areas subjected to surgical excisions together with a margin of normal tissue on the fifth and sixth days of cyclopamine applications when the BCC's had lost most of their pre-treatment areas but still possessed few regions that, although markedly decreased in height, had not yet completely disappeared and therefore had residual tumor cells for microscopic analyses.
  • Fig 2A and Fig 2B show, on tissue sections, the skin areas corresponding to the visually disappeared tumor nodules. The tumors are seen to have disappeared to leave behind large cystic structures containing little material inside and no detectable tumor cells.
  • Fig 2C shows microscopic appearance of a skin area that contained still visible BCC in vivo. These regions are seen to contain residual BCC's displaying large cysts in the tumor center and smaller cystic structures of various sizes located among the residual BCC cells towards the periphery.
  • Fig 2D and Fig 2E show 1000X magnified appearances from the interior and palisading peripheral regions of these residual BCC's and show the presence of massive apoptotic activity among the residual BCC cells regardless of the tumor region.
  • These high magnifications show greatly increased frequency of the BCC cells displaying apoptotic morphology and formation of the cystic structures by the apoptotic removal of cells as exemplified on Fig 2D by the imminent joining together of the three smaller cysts into a larger one upon removal of the apoptotic septal cells.
  • Fig 2F shows that the BCC's treated with the placebo cream (i.e. the cream preparation identical to the cyclopamine cream except for the absence of cyclopamine in placebo) show, by contrast, the typical neoplastic BCC cells and no detectable apoptotic activity.
  • the placebo cream i.e. the cream preparation identical to the cyclopamine cream except for the absence of cyclopamine in placebo
  • Fig 3A, Fig 3B and the quantitative data on Table I show that, while Ber-Ep4 strongly labels all peripheral palisading cells and over 90% of the interior cells of the placebo-treated BCC's, none of the residual peripheral or interior cells of the cyclopamine-treated BCC's are labelled by Ber-Ep4. Differentiation of the BCC's under the influence of cyclopamine, hitherto unknown by any other means and highly unusual because of achievement of it in vivo and in all cells by immunohistochemical criteria, has independent value in the treatment of cancer.
  • Another differentiation marker, Ulex Eumpaeus lectin type 1 normally does not label the BCC's or the basal layer cells of normal epidermis but labels the differentiated upper layer cells.
  • Fig 3C showing the heterogenous labelling of the residual cells of cyclopamine-treated BCC's with this lectin, shows differentiation of some of the BCC cells beyond the differentiation step detected by Ber-Ep4 all the way to the step detected by Ulex Eumpaeus lectin type 1.
  • the p53 is a master regulator of the cellular response to DNA-damage. Amount of this protein is known to increase in the cell nucleus following exposure of cells to genotoxic agents. When the DNA-damage is increased beyond a threshold, p53 serves for the apoptotic death of cells. Radiation therapy of cancer and the genotoxic cancer chemotherapeutics that are currently common, act largely by this mechanism, i.e. by causation of apoptosis secondary to the damaging of DNA.
  • the monoclonal antibody DO-7 can bind both normal and missense mutant (i.e., nonfunctional) forms of p53 and is known to be capable of detecting the increase of p53 in the cells following exposure to DNA-damaging agents.
  • Fig 3D, Fig 3E and the quantitative data in Table I show that both the DO-7 labelling intensity and the frequency of labelled cells are markedly decreased in cyclopamine-treated BCC's in comparison to the placebo-treated BCC's.
  • cyclopamine causes, not an increase, but rather a decrease of p53 in the nuclei of cyclopamine-treated BCC cells. Since expression of p53 is known to decrease in epidermal cells upon differentiation, the decreased DO-7 labelling of the cyclopamine-treated BCC's is likely to be secondary to the cyclopamine-induced differentiation of the BCC cells.
  • Fig 4A to Fig 4D show Ber-Ep4 labelling of the normal skin tissue found on and around the cyclopamine- treated BCC's. Different epidermal areas that were treated with cyclopamine are seen in Fig 4A, Fig 4B and Fig 4C to display normal pattern of labelling with Ber-Ep4, i.e. labelling of the basal layer cells. Similarly Fig 4D shows normal Ber-Ep4 labelling of a hair follicle exposed to cyclopamine. Thus the undifferentiated cells of normal epidermis and of hair follicles are preserved despite being exposed to the same schedule and doses of cyclopamine as the BCC's.
  • Fig 1A, 1B, 1C, 1D Rapid regressions of the cyclopamine-treated BCC's as indicated by disappeared tumor regions (exemplified by arrows), markedly decreased height from skin surface and by a loss of translucency in less than a week.
  • 1 A BCC, located on left nasolabial fold, prior to treatment.
  • 1 B Same BCC on the fifth day of topical cyclopamine treatment.
  • 1 C BCC, located on forehead, prior to tretment.
  • 1D Same BCC on the sixth day of topical cyclopamine treatment.
  • Fig 2A, 2B, 2C, 2D, 2E, 2F Microscopic appearances of the cyclopamine- and placebo-treated BCC's, showing the cyclopamine-induced massive apoptotic death and removal of the tumor cells and the disappearance of tumor nodules to leave behind cystic spaces with no tumor cells. Skin areas corresponding to the pre-treatment positions of the BCC's were excised surgically on the fifth and sixth days of cyclopamine exposure with a margin of normal tissue and subjected to conventional fixation, sectioning and hematoxyfene-eosine staining for microscopic analyses.
  • 2A Large cyst in the dermis corresponding to the position of a disappeared tumor nodule showing no residual tumor cells.
  • 2B Similar cysts in another dermal area that contained BCC prior to, but not after, treatment with cyclopamine.
  • 2C Low power view of an area of the BCC shown on Fig 1 D showing residual cells and formation of a large cyst by the joining together of the numerous smaller cysts in between these cells.
  • 2D High power view from an interior region of the same residual BCC as in Fig 2C showing greatly increased frequency of the apoptotic cells and the formation as well as enlargement of the cysts by the apoptotic removal of the BCC cells.
  • 2E High power view from from a peripheral region of the same residual BCC as in Fig 2C also showing greatly increased frequency of the apoptotic cells and the formation of cysts by the apoptotic removal of BCC cells.
  • 2F High power view from an internal area of a placebo-treated BCC showing typical neoplastic cells of this tumor and the absence of apoptosis.
  • Original magnifications are 100X for 2A, 2B, 2C and 1000X for 2D, 2E, 2F.
  • Fig 3A, 3B, 3C, 3D, 3E, 3F, 3G Immunohistochemical analyses of the cyclopamine- and placebo-treated BCC's showing differentiation of all residual BCC cells under the influence of cyclopamine and the decrease of p53 expression in BCC's following exposure to cyclopamine.
  • 3A and 3B Absence of staining with the monoclonal antibody Ber-E ⁇ 4 in all residual cells of cyclopamine-treated BCC (3A) contrasted with the strong staining in placebo-treated BCC (3B) showing that all residual cells in the cyclopamine-treated BCC's are differentiated to or beyond a step detected by Ber-Ep4.
  • Ber-Ep4 is a known differentiation marker that stains the BCC cells as well as the undifferentiated cells of the normal epidermis basal layer and of hair follicles but not the differentiated upper layer cells of normal epidermis.
  • 3C Heterogenous labelling of the residual cells of a cyclopamine-treated BCC with the Ulex Eumpaeus lectin type 1 showing differentiation of some of the BCC cells all the way to the step detected by this lectin which normally does not label the BCC's or the basal layer cells of the normal epidermis but labels the differentiated upper layer cells.
  • 3D and 3E Decreased expression of p53 as detected by the monoclonal antibody DO-7 in cyclopamine-treated BCC's (3D) in comparison to the placebo-treated BCCs (3E). Expression of p53 is
  • Fig4A, 4B, 4C, 4D Normal pattern of labelling of the cydopamihe-ireated normal skin with Ber-Ep4 showing that the undifferentiated cells of normal epidermis and of hair follicles are preserved despite being exposed to the same schedule and doses of cyclopamine as the BCC's.
  • 4A Ber-Ep4 labelling of the basal layer cells of the epidermis treated with cyclopamine.
  • 4B and 4C Higher power views from different areas of cyclopamine-treated epidermis showing Ber-Ep4 labelling of the basal cells.4D : High
  • Means ⁇ standart deviations from at least 16 randomly selected high-power (1000 X) fields of the tissue sections of each tumor group are shown, p ⁇ 0.001 for the placebo vs cyclopamine-treated tumors for all the parameters, both for the palisading peripheral and the non-palisading (interior) tumor areas.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PCT/TR2001/000027 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors Ceased WO2002078703A1 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
CN018234429A CN1525859B (zh) 2001-07-02 2001-07-02 环杷明在制备治疗基底细胞癌及其它肿瘤的药物中的应用
DK01952097T DK1401438T3 (da) 2001-07-02 2001-07-02 Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer
EP10163813.8A EP2216022B1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
AU2001272892A AU2001272892B8 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
EP20140196071 EP2862570A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
EP01952097A EP1401438B1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
EP05008758A EP1561464A3 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
ES01952097T ES2250434T3 (es) 2001-07-02 2001-07-02 Utilizacion de ciclopamina en el tratamiento del carcinoma de celulas basales y de otros tumores.
AT01952097T ATE305300T1 (de) 2001-07-02 2001-07-02 Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
JP2002576969A JP2004536045A (ja) 2001-07-02 2001-07-02 基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法
DE60113733T DE60113733T2 (de) 2001-07-02 2001-07-02 Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
BR0117063-5A BR0117063A (pt) 2001-07-02 2001-07-02 Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
ES10163813.8T ES2534400T3 (es) 2001-07-02 2001-07-02 Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores
CA2452151A CA2452151C (en) 2001-07-02 2001-07-02 Use of cyclopamine, an inducer of the differentiation and apoptosis of the basal cell carcinoma (bcc) cells, in the treatment of bcc's and other tumors that use the hedgehog/smoothened pathway for proliferation of apoptosis
EP02736467A EP1411938B1 (en) 2001-07-02 2002-04-19 Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
CA002452152A CA2452152A1 (en) 2001-07-02 2002-04-19 Use of cyclopamine in the treatment of psoriasis
PT02736467T PT1411938E (pt) 2001-07-02 2002-04-19 Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase
PCT/TR2002/000017 WO2002078704A1 (en) 2001-07-02 2002-04-19 Use of cyclopamine in the treatment of psoriasis
AT02736467T ATE299022T1 (de) 2001-07-02 2002-04-19 Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis
ES02736467T ES2246011T3 (es) 2001-07-02 2002-04-19 Utilizacion de ciclopamina para la preparacion de un medicamento para el tratamiento de la psoriaris.
DK02736467T DK1411938T3 (da) 2001-07-02 2002-04-19 Anvendelse af cyclopamin til fremstilling af et medikament til behandling af psoriasis
DE60204966T DE60204966T2 (de) 2001-07-02 2002-04-19 Verwendung von Cyclopamin zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
RU2004103074/15A RU2312661C2 (ru) 2001-07-02 2002-04-19 Применение циклопамина при лечении псориаза
CNB02813429XA CN1230169C (zh) 2001-07-02 2002-04-19 环杷明在银屑病治疗中的应用
KR1020097022024A KR20090125833A (ko) 2001-07-02 2003-03-17 건선 및 다른 피부 질환의 치료를 위한 Ｈｈ/Ｓｍｏ 신호의 선택적 억제제의 용도
US10/682,584 US7893078B2 (en) 2001-07-02 2003-10-09 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
US10/682,662 US7605167B2 (en) 2001-07-02 2003-10-09 Use of cyclopamine in the treatment of psoriasis
US11/874,631 US8025893B2 (en) 2001-07-02 2007-10-18 Use of a specific inhibitor of hedgehog/smoothened signaling on hyperpigmented skin to obtain decrease of pigmentation
US11/874,653 US7629352B2 (en) 2001-07-02 2007-10-18 Pharmaceutical composition comprising a corticosteroid and a specific inhibitor of hedgehog/smoothened signaling
US12/460,620 US9757361B2 (en) 2001-07-02 2009-07-22 Treatment of psoriasis and of other skin disorders associated with inhibition of differentiation of epidermal cells
JP2010028010A JP5424923B2 (ja) 2001-07-02 2010-02-10 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
US12/930,677 US20110104254A1 (en) 2001-07-02 2011-01-13 Medicament for treatment of tumors wherein hedgehog/smoothened signaling is employed for inhibition of apoptosis of the tumor cells
JP2013193304A JP2014028834A (ja) 2001-07-02 2013-09-18 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
US15/530,513 US20170326118A1 (en) 2001-07-02 2017-01-23 Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2001/000017 Continuation-In-Part WO2001080702A2 (en) 2000-04-20 2001-04-20 Foldable glass-holding racks
PCT/TR2002/000017 Continuation-In-Part WO2002078704A1 (en) 2001-07-02 2002-04-19 Use of cyclopamine in the treatment of psoriasis

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/TR2002/000017 Continuation-In-Part WO2002078704A1 (en) 2001-07-02 2002-04-19 Use of cyclopamine in the treatment of psoriasis
US10/682,662 Continuation-In-Part US7605167B2 (en) 2001-07-02 2003-10-09 Use of cyclopamine in the treatment of psoriasis
US10/682,584 Continuation-In-Part US7893078B2 (en) 2001-07-02 2003-10-09 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (2)

Publication Number Publication Date
WO2002078703A1 true WO2002078703A1 (en) 2002-10-10
WO2002078703A8 WO2002078703A8 (en) 2003-06-12

Family

ID=21619326

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2001/000027 Ceased WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
PCT/TR2002/000017 Ceased WO2002078704A1 (en) 2001-07-02 2002-04-19 Use of cyclopamine in the treatment of psoriasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/TR2002/000017 Ceased WO2002078704A1 (en) 2001-07-02 2002-04-19 Use of cyclopamine in the treatment of psoriasis

Country Status (14)

Country Link
EP (4) EP1561464A3 (enExample)
JP (3) JP2004536045A (enExample)
KR (1) KR20090125833A (enExample)
CN (2) CN1525859B (enExample)
AT (2) ATE305300T1 (enExample)
AU (1) AU2001272892B8 (enExample)
BR (1) BR0117063A (enExample)
CA (1) CA2452151C (enExample)
DE (2) DE60113733T2 (enExample)
DK (2) DK1401438T3 (enExample)
ES (3) ES2250434T3 (enExample)
PT (1) PT1411938E (enExample)
RU (1) RU2312661C2 (enExample)
WO (2) WO2002078703A1 (enExample)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088964A1 (en) * 2002-04-19 2003-10-30 Sinan Tas Use of cyclopamine in the treatment of psoriasis and other skin disorders
WO2008109184A1 (en) * 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
WO2010080817A3 (en) * 2009-01-06 2010-11-25 Utah State University Carbohydrate-cyclopamine conjugates as anticancer agents
US7964590B2 (en) 2007-03-07 2011-06-21 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US8227509B2 (en) 2006-12-28 2012-07-24 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US8324361B2 (en) 2005-10-31 2012-12-04 Oncomed Pharmaceuticals, Inc. Nucleic acid molecules encoding soluble frizzled (FZD) receptors
US8501472B2 (en) 2007-01-24 2013-08-06 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US8507442B2 (en) 2008-09-26 2013-08-13 Oncomed Pharmaceuticals, Inc. Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
US9089556B2 (en) 2000-08-03 2015-07-28 The Regents Of The University Of Michigan Method for treating cancer using an antibody that inhibits notch4 signaling
US9157904B2 (en) 2010-01-12 2015-10-13 Oncomed Pharmaceuticals, Inc. Wnt antagonists and methods of treatment and screening
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9238672B2 (en) 2007-12-27 2016-01-19 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
US9850311B2 (en) 2005-10-31 2017-12-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9879293B2 (en) 2009-08-05 2018-01-30 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
WO2018048367A1 (en) 2017-01-23 2018-03-15 Tas Sinan Medicaments and uses in treatment of cancer and other pathological conditions associated with aging
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
WO2023027648A1 (en) 2021-09-13 2023-03-02 Tas Sinan Effective interventions with aging and diseases of aging of human and their consequences

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001272892B8 (en) * 2001-07-02 2006-05-04 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
SG175691A1 (en) * 2006-10-31 2011-11-28 Us Gov Health & Human Serv Smoothened polypeptides and methods of use
CN101990542A (zh) * 2008-02-08 2011-03-23 德克萨斯大学董事会 环巴胺酒石酸盐及其用途
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
CN104740633A (zh) * 2013-12-26 2015-07-01 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
US20170231968A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052534A1 (en) * 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
WO2000041545A2 (en) * 1999-01-13 2000-07-20 Ontogeny, Inc. Regulators of the pct or smoothened pathway, compositions and uses related thereto
WO2001027135A2 (en) * 1999-10-13 2001-04-19 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
CN1195513C (zh) * 1998-09-23 2005-04-06 研究发展基金会 生良酚、生育三烯酚、其它苯并二氢吡喃和侧链衍生物,及其用途
JP2003501395A (ja) * 1999-06-08 2003-01-14 ローランティス・リミテッド 治療的使用
WO2001040438A2 (en) * 1999-11-30 2001-06-07 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
AU2001272892B8 (en) * 2001-07-02 2006-05-04 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052534A1 (en) * 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
WO2000041545A2 (en) * 1999-01-13 2000-07-20 Ontogeny, Inc. Regulators of the pct or smoothened pathway, compositions and uses related thereto
WO2001027135A2 (en) * 1999-10-13 2001-04-19 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERMAN DAVID M ET AL: "Inhibition of prostate morphogenesis by the Sonic hedgehog pathway inhibitor cyclopamine.", JOURNAL OF UROLOGY, vol. 163, no. 4 Suppl., April 2000 (2000-04-01), 95th Annual Meeting of the American Urological Association, Inc.;Atlanta, Georgia, USA; April 29, 2000-May 04, 1999, pages 204, XP008001018, ISSN: 0022-5347 *
DETMER K ET AL: "Erythroid differentiation in vitro is blocked by cyclopamine, an inhibitor of hedgehog signaling.", DEVELOPMENTAL BIOLOGY, vol. 222, no. 1, 1 June 2000 (2000-06-01), Fifty-ninth Annual Meeting of the Society for Developmental Biology;Boulder, Colorado, USA; June 07-11, 2000, pages 242, XP008001023, ISSN: 0012-1606 *
HOPYAN SEVAN ET AL: "Indian Hedgehog and Parathyroid hormone related protein signaling in cartilage tumors of bone.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 206, XP008001019, ISSN: 0197-016X *
TAIPALE ET AL: "Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 406, no. 6799, 31 August 2000 (2000-08-31), pages 1005 - 1009, XP002166408, ISSN: 0028-0836 *

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420885B2 (en) 2000-08-03 2013-04-16 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US9089556B2 (en) 2000-08-03 2015-07-28 The Regents Of The University Of Michigan Method for treating cancer using an antibody that inhibits notch4 signaling
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US7629352B2 (en) 2001-07-02 2009-12-08 Sinan Tas Pharmaceutical composition comprising a corticosteroid and a specific inhibitor of hedgehog/smoothened signaling
US9757361B2 (en) 2001-07-02 2017-09-12 Sinan Tas Treatment of psoriasis and of other skin disorders associated with inhibition of differentiation of epidermal cells
WO2003088964A1 (en) * 2002-04-19 2003-10-30 Sinan Tas Use of cyclopamine in the treatment of psoriasis and other skin disorders
US9732139B2 (en) 2005-10-31 2017-08-15 Oncomed Pharmaceuticals, Inc. Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor
US8765913B2 (en) 2005-10-31 2014-07-01 Oncomed Pharmaceuticals, Inc. Human frizzled (FZD) receptor polypeptides and methods of use thereof for treating cancer and inhibiting growth of tumor cells
US9228013B2 (en) 2005-10-31 2016-01-05 OncoMed Pharmaceuticals Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cell
US9850311B2 (en) 2005-10-31 2017-12-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8324361B2 (en) 2005-10-31 2012-12-04 Oncomed Pharmaceuticals, Inc. Nucleic acid molecules encoding soluble frizzled (FZD) receptors
US10314827B2 (en) 2006-12-28 2019-06-11 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US10045970B2 (en) 2006-12-28 2018-08-14 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US9951083B2 (en) 2006-12-28 2018-04-24 Infinity Pharmaceuticals, Inc. Cyclopamine analogs
US8227509B2 (en) 2006-12-28 2012-07-24 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US10406139B2 (en) 2006-12-28 2019-09-10 Infinity Pharmaceuticals, Inc. Cyclopamine analogs
US10821102B2 (en) 2006-12-28 2020-11-03 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US8785635B2 (en) 2006-12-28 2014-07-22 Infinity Pharmaceuticals, Inc. Cyclopamine analogs
US11007181B2 (en) 2006-12-28 2021-05-18 Infinity Pharmaceuticals, Inc. Cyclopamine analogs
US9669011B2 (en) 2006-12-28 2017-06-06 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US11602527B2 (en) 2006-12-28 2023-03-14 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US9145422B2 (en) 2006-12-28 2015-09-29 Infinity Pharmaceuticals, Inc. Methods of use of cyclopamine analogs
US9492435B2 (en) 2006-12-28 2016-11-15 Infinity Pharmaceuticals, Inc. Cyclopamine analogs
US8501472B2 (en) 2007-01-24 2013-08-06 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US8426436B2 (en) 2007-03-07 2013-04-23 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
CN101687877B (zh) * 2007-03-07 2014-07-23 无限发现股份有限公司 杂环环杷明类似物及其使用方法
WO2008109184A1 (en) * 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
US7648994B2 (en) 2007-03-07 2010-01-19 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
US7964590B2 (en) 2007-03-07 2011-06-21 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
US7994191B2 (en) 2007-03-07 2011-08-09 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
US8293760B2 (en) 2007-03-07 2012-10-23 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
US8431566B2 (en) 2007-03-07 2013-04-30 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
US9238672B2 (en) 2007-12-27 2016-01-19 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8507442B2 (en) 2008-09-26 2013-08-13 Oncomed Pharmaceuticals, Inc. Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8
US9573998B2 (en) 2008-09-26 2017-02-21 Oncomed Pharmaceuticals, Inc. Antibodies against human FZD5 and FZD8
US9273139B2 (en) 2008-09-26 2016-03-01 Oncomed Pharmaceuticals, Inc. Monoclonal antibodies against frizzled
US8975044B2 (en) 2008-09-26 2015-03-10 Oncomed Pharmaceuticals, Inc. Polynucleotides encoding for frizzled-binding agents and uses thereof
WO2010080817A3 (en) * 2009-01-06 2010-11-25 Utah State University Carbohydrate-cyclopamine conjugates as anticancer agents
US9879293B2 (en) 2009-08-05 2018-01-30 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
US9157904B2 (en) 2010-01-12 2015-10-13 Oncomed Pharmaceuticals, Inc. Wnt antagonists and methods of treatment and screening
US9579361B2 (en) 2010-01-12 2017-02-28 Oncomed Pharmaceuticals, Inc. Wnt antagonist and methods of treatment and screening
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
US9499630B2 (en) 2010-04-01 2016-11-22 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9879025B2 (en) 2010-09-14 2018-01-30 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
US9987357B2 (en) 2013-02-04 2018-06-05 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a WNT pathway inhibitor
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US10695344B2 (en) 2015-06-04 2020-06-30 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US11413283B2 (en) 2015-06-04 2022-08-16 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
WO2018048367A1 (en) 2017-01-23 2018-03-15 Tas Sinan Medicaments and uses in treatment of cancer and other pathological conditions associated with aging
WO2023027648A1 (en) 2021-09-13 2023-03-02 Tas Sinan Effective interventions with aging and diseases of aging of human and their consequences

Also Published As

Publication number Publication date
EP2216022B1 (en) 2015-01-07
EP1561464A3 (en) 2007-04-25
AU2001272892B2 (en) 2006-03-16
RU2004103074A (ru) 2005-05-10
AU2001272892B8 (en) 2006-05-04
JP2004536045A (ja) 2004-12-02
DK1401438T3 (da) 2006-02-13
EP2216022A1 (en) 2010-08-11
DE60113733T2 (de) 2006-06-29
EP1401438B1 (en) 2005-09-28
EP2862570A1 (en) 2015-04-22
CN1525859A (zh) 2004-09-01
KR20090125833A (ko) 2009-12-07
CN1230169C (zh) 2005-12-07
ES2534400T3 (es) 2015-04-22
PT1411938E (pt) 2005-11-30
WO2002078704A1 (en) 2002-10-10
DE60113733D1 (de) 2006-02-09
DK1411938T3 (da) 2005-11-07
DE60204966D1 (de) 2005-08-11
CN1525859B (zh) 2010-05-05
CA2452151C (en) 2012-01-03
JP5424923B2 (ja) 2014-02-26
RU2312661C2 (ru) 2007-12-20
ES2250434T3 (es) 2006-04-16
EP1401438A1 (en) 2004-03-31
CA2452151A1 (en) 2002-10-10
ES2246011T3 (es) 2006-02-01
WO2002078703A8 (en) 2003-06-12
CN1522146A (zh) 2004-08-18
JP2014028834A (ja) 2014-02-13
ATE299022T1 (de) 2005-07-15
EP1561464A2 (en) 2005-08-10
DE60204966T2 (de) 2006-05-18
BR0117063A (pt) 2004-07-27
JP2010132691A (ja) 2010-06-17
ATE305300T1 (de) 2005-10-15

Similar Documents

Publication Publication Date Title
EP1401438B1 (en) Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
AU2001272892A1 (en) Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
US7893078B2 (en) Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
Engelhard et al. Therapeutic effects of sodium butyrate on glioma cells in vitro and in the rat C6 glioma model
JP2009143963A (ja) 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
US20170326118A1 (en) Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
RU2308948C2 (ru) Применение циклопамина для лечения базально-клеточной эпителиомы (карциномы) и других опухолей
Abdalla et al. Actinic Keratosis, Other Precursors, and Squamous Cell Tumors
HK1096597A (en) Use of cyclopamine in the treatment of psoriasis and other skin disorders
CN101904852A (zh) 环杷明在治疗基底细胞癌及其它肿瘤中的应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BR CA CN DE DK ES FI GB IN JP MX NO PT RU SE TR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 41/2002 DELETE "(71) APPLICANT: TAS, SINAN ¢TR/TR!; YASEMIN SOKAK 6, SAHILEVLERI, NARLIDERE, IZMIR, 35320 (TR)." AND UNDER (71, 72) ADD "TAS, SINAN ¢TR/TR!; YASEMIN SOKAK 6, SAHILEVLERI, NARLIDERE, IZMIR, 35320 (TR)."

WWE Wipo information: entry into national phase

Ref document number: 2001952097

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10682662

Country of ref document: US

Ref document number: 10682584

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2452151

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002576969

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20018234429

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 180/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2001272892

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001952097

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001952097

Country of ref document: EP